Atracurium is an intermediate-acting nondepolarizing Neuromuscular Blocker. Routinely is used for the neuromuscular blockade in most pediatric surgeries. Cis-atracurium is an stereoisomer approximately 4 times as potent as atracurium. In contrast to atracurium, Cis-atracurium is devoid of chemically mediated histamine release.
Development Of Manufacturing Technology For Three Pharmaceutical Ingredients
Nearly 40% of anaesthetists surveyed by the Royal College of Anaesthetists have said they are not confident that they will have sufficient supplies of anaesthetic drugs for COVID-19 patients over the next month. The survey of 2,174 anaesthetists added that 14% currently “do not have access to all the usual drugs”. This comes after the government warned on 16 April 2020 that supplies of atracurium and cisatracurium were expected to run out “over the coming days” due to increased demand from COVID-19 patients. The survey, published on 23 April 2020, said: “Departments of anaesthesia and intensive care are currently collaborating with each other and with pharmacists to ensure drugs are prioritised appropriately across the two areas.”
The Department of Health and Social Care (DHSC) announced yesterday, 16 April 2020 that the UK’s supplies of the vital muscle relaxant medicines (atracurium and cisatracurium) used in patients on mechanical ventilators will be exhausted in the next few days via the MHRA.
In April 2019 CF was successfully re-audited by IIDC Austria and received a HALAL certification for four of our active pharmaceutical ingredients:
Neuromuscular blocking agent containing medicines (NMBAs) are used to cause paralysis during anaesthesia.
Mylan Pharm's Generic Atracurium Besylate Receives Approval In US
Mylan Labs Generic Atracurium Besylate Receives Approval In US
Aurobindo`s Generic Atracurium Besylate Injection Approved in USA For Anesthesia
Sagent Pharmaceuticals Inc, Ongoing Class II recall of Atracurium Besylate Injection, USP, 100 mg per 10 mL (10 mg per mL), Rx Only, 10 mL Multi-Dose Vial, For Intravenous Injection, Mfd. for: Sagent Pharmaceuticals, Schaumberg, IL 60195, NDC 25021-672-10 because of Lack of Assurance of Sterility: Recall initiated due to FDA observations pertaining to aseptic and GMP practices at the manufacturers site potentially impacting product sterility.